Navigation Links
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Date:12/22/2009

reviewed by the FDA under Priority Review with a PDUFA date of February 28, 2010. The CHMP has granted accelerated review for the EU MAA. - The FDA recently completed the pre-approval inspections of Shire's Cambridge and Lexington Massachusetts facilities for the manufacturing and testing of velaglucerase alfa. These inspections were an important milestone in the review and approval process for the U.S. NDA for velaglucerase alfa. - Shire continues to work with U.S. physicians to provide access to velaglucerase alfa under an FDA-approved treatment protocol. In Europe and other countries outside the U.S., patients continue to receive the product through pre-approval access programs.

About REPLAGAL(R) (agalsidase alfa)

REPLAGAL is a human form of enzyme alpha-galactosidase A (a-Gal A) manufactured in a human cell line by gene activation. REPLAGAL is approved in 45 countries worldwide. REPLAGAL is not currently approved for commercial sale in the U.S.

REPLAGAL is the only human-cell-line-derived form of enzyme replacement therapy (ERT) that is indicated for the long-term treatment of patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency).

About Fabry disease

Fabry disease is a lysosomal storage disorder (LSD) that interferes with the body's ability to break down a specific fatty substance (globotriaosylceramide or Gb3) which accumulates within the body due to deficiency of a specific enzyme (alpha-galactosidase A).

Fabry disease affects both males and females and can present with a number of signs or symptoms of variable degree, such as cardiovascular and/or renal dysfunction, intense or burning pain, heat intolerance, skin lesions, gastrointestinal complaints, hearing loss, and ocular problems.

Lifespan is typically reduced in patients with Fabry disease by a
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
2. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
3. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
4. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
5. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
6. Shire Continues to Deliver Excellent Growth From Core Products
7. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
8. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
9. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
10. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
11. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Cochlear Limited ... hearing solutions, announced today the US Food and ... Profile™ Implant with Slim Straight Electrode (CI522). Built ... in close collaboration with the world,s leading surgeons, ... platform designed to provide the most discreet appearance ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/34xqr7/2015_new ) has announced the addition of ... Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, ... their offering. 2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape is ...
(Date:7/1/2015)... July 1, 2015  goBalto, Inc., the leading ... today unprecedented growth in serving pharmaceutical, biotech and ... to speed clinical trials and restrain costs, but ... methods have stalled these efforts," said Sujay ... clinical trials has encouraged Industry leaders, to embrace ...
Breaking Medicine Technology:Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 32015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2
(Date:7/1/2015)... ... 2015 , ... As if mood swings, cramps and child labor weren’t enough ... leg pain. Northeast Houston Vein Center is offering tips on the treatment options for ... is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, restless legs, cramps ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of IBM software products, announced today that it has received trademark protection for ... display and detailed analysis of data from multiple sources providing an environment where ...
(Date:7/1/2015)... ... 2015 , ... A Priority Setting Partnership put in place ... they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted an ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the mesothelioma ...
(Date:7/1/2015)... York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t ... fell into her lap, so too did her support of the practice; a terrible car ... , In her new book, “Do I Need It ? (And What if I ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... the battle against malignant brain tumors, dual implantation ... showed promising results in a study led by ... of Cincinnati (UC) and University Hospital. , The ... Journal of Neurosurgery, revealed that patients treated with ...
... Gornick LLP, Bailey Perrin Bailey LLP and Weitz &, ... United, States District Court for the Eastern District of New York ... Co., Inc. and Schering-Plough Corporation., ... the law,firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, ...
... Five Such Cases Known Worldwide, NEW HYDE PARK, N.Y., ... physicians at LIJ Medical,Center, 25-year-old Stacey Gayle can now look ... radio. At a news conference today, Ms.,Gayle and her doctors ... robbed her of her health, but of the very important,gift ...
... Jan Marini Skin Research,Inc. (JMSR; http://www.janmarini.com ) today ... Age Intervention Eyelash Conditioner,and Age Intervention Masses of Lashes ... patent infringement lawsuit by Allergan Pharmaceutical as,one reason for ... suspend,these products while we strategically review our options," said ...
... general use, experts caution , , THURSDAY, Jan. 17 (HealthDay News)-- Some ... modifies the body,s immune response. , A study in the Jan. ... no history of heart attacks, as well as those in a ... and of subsequent hospitalizations with such a treatment. , But ...
... a lack of knowledge of health risks posed by ... cell phone technology and use continues to expand and evolve, ... potential health risks associated with long-term exposure to radiofrequency energy. ... women and fetuses -- as well as workers subject to ...
Cached Medicine News:Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music 2Health News:Jan Marini Skin Research Suspends Sales of Popular Eyelash Products 2Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: